PRODUCT INFORMATION



Methylcarbamyl PAF C-8

Catalog No. 9000332

Formal Name:	1-O-octyl-2-O-(N- methylcarbamoyl)- <i>sn</i> -glyceryl-3- phosphorylcholine	
MF:	$C_{18}H_{39}N_2O_7P$	\sim \sim \sim \sim \sim \sim $^{\circ}$
FW:	426.5	
Purity:	≥98%	\rightarrow + \rightarrow $0^{-P} = 0$
Supplied as:	A solution in ethanol	
Storage:	-20°C	0-
Stability:	≥2 years	
Information represen	ts the product specifications. Batch specifi	c analytical results are provided on each certificate of analysis.

Laboratory Procedures

Methylcarbamyl PAF C-8 is supplied as a solution in ethanol. To change the solvent, simply evaporate the ethanol under a gentle stream of nitrogen and immediately add the solvent of choice. Solvents such as ethanol, DMSO, and dimethyl formamide purged with an inert gas can be used. The solubility of methylcarbamyl PAF C-8 in these solvents is approximately 25 mg/ml.

Further dilutions of the stock solution into aqueous buffers or isotonic saline should be made prior to performing biological experiments. Ensure that the residual amount of organic solvent is insignificant, since organic solvents may have physiological effects at low concentrations. If an organic solvent-free solution of methylcarbamyl PAF C-8 is needed, it can be prepared by evaporating the ethanol and directly dissolving the neat oil in aqueous buffers. The solubility of methylcarbamyl PAF C-8 in PBS, pH 7.2, is approximately 25 mg/ml. We do not recommend storing the aqueous solution for more than one day.

Description

Methylcarbamyl PAF C-8 is the C-8 analog of methylcarbamyl PAF C-16. Methylcarbamyl PAF C-16 is a stable analog of PAF C-16 with a half-life greater than 100 minutes in platelet poor plasma due to its resistance to degradation by PAF-AH.^{1,2} It is nearly equipotent with PAF C-16 in its ability to induce platelet aggregation both in isolated platelets and in platelet-rich plasma.¹ In NRK-49 cells overexpressing the PAF receptor, both PAF C-16 and methylcarbamyl PAF C-16 cause the induction of c-Myc, c-fos, and the activation of mitogen-activated protein kinase.² Methylcarbamyl PAF C-16 induces G₁ phase cell cycle arrest, suggesting a potential role for PAF in the inhibition of oncogenic transformation.²

References

- 1. Hadváry, P., Cassal, J.-M., Hirth, G., et al. Structural requirements for the activation of blood platelets by analogues of platelet-activating factor (PAF-acether). Platelet-Activating Factor INSERM Symposium 23, 57-64 (1983).
- 2. Kume, K. and Shimizu, T. Platelet-activating factor (PAF) induces growth stimulation, inhibition, and suppression of oncogenic transformation in NRK cells overexpressing the PAF receptor. J. Biol. Chem. 272, 22898-22904 (1997).

WARNING THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFFTY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

uyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 02/07/2024

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD ANN ARBOR, MI 48108 · USA PHONE: [800] 364-9897 [734] 971-3335 FAX: [734] 971-3640 CUSTSERV@CAYMANCHEM.COM WWW.CAYMANCHEM.COM